68 results about "Osteoprotegerin" patented technology

A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

A novel polypeptide, osteoprotegerin binding protein, involved in osteoclast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog, or derivative thereof, vectors and host cells for production, and binding assays are described. Antibodies specifically binding osteoprotegerin binding protein are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.

Devices and methods for stimulation of the vagus nerve to modulate (e.g., reduce, suppress, etc.) bone erosion. Methods and apparatus for modulating bone erosion may modulate levels of Receptor Activator for Nuclear Factor κ B Ligand (RANKL), and / or to modulate (increase, enhance, etc.) osteoprotegerin (OPG) and / or OPG / RANKL ratio. Devices may include electrical stimulation devices that may be implanted, and may be activated to apply current for a proscribed duration, followed by a period without stimulation.

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.

The invention relates to the use of osteoprotegerin for treatment and / or prevention of fibrotic diseases, in particular of scleroderma.

The invention discloses an agent box for detecting female osteoporosis impressionable heredity risks. The agent comprises specificity primer pair and specificity fluorescent detecting probe pair for detecting synchronously number rs1800795 SNP site on encode interleukins 6 gene, number rs2073618 SNP site on bone protection element TNFRSF11B gene, number rs1800629 SNP site on tumor necrosis factor-Alpha, number rs1544410 and rs731236 SNP site on vitamin D receptor gene, and general component for detecting fluorescent definite quantity PCR etc.. The agent box of the invention assesses female osteoporosis impressionable heredity risks by detecting synchronously mononucleotide polymorphism site gene type correlative closely to osteoporosis impressionable heredity risks.

The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

The invention relates to the field of diagnosis kits, particularly to application of OPN, GDF15, NSE, TRAP5 and OPG to preparation of early liver cancer diagnosis detecting reagents or kits. The invention also discloses a kit which is used for diagnosing early liver cancer in a combined mode by detecting content of OPN, GDF15, NSE, TRAP and OPG in plasma. The kit has the advantages of being high in specificity and sensitivity, can be applied to early diagnosis of liver cancer, therapeutic effect evaluation during treatment and post-treatment metastasis and recurrence monitoring and can provide detecting results earlier than clinical symptoms. The kit and detecting technology is mature, short in cycle and good in specificity.

Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.

The invention relates to a method for selecting and breeding Wuding chickens based on osteoprotegerin blood biochemical markers, and belongs to the technical field of poultry blood biochemical markers. The method comprises the following steps: 1) collecting blood samples of Wuding chickens to be detected, preparing serum and detecting osteoprotegerin (OPG) concentration thereof; and 2) comparing the concentration measured in the step 1) with the blood biochemical markers of the Wuding chickens to classify the Wuding chickens to be detected into the Wuding chickens with normal bone developmentand the Wuding chickens with abnormal bone development. By measuring change of concentration of osteoprotegerin in the serum of the Wuding chickens with normal bone development and the Wuding chickenswith abnormal bone development and combining the detected bone density and bone strength of the Wuding chickens, the method gives blood biochemical markers of the Wuding chickens with normal bone development and the Wuding chickens with abnormal bone development to screen out the high-quality chickens, thereby providing theoretical basis for early selection of the Wuding chickens, and providing anew idea for research on the breeding method of the Wuding chickens and breeding of Yunnan local chicken breeds.

The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and / or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.

The present invention relates to a herbal mixture extract of Pleurotus eryngii, Acanthopanacis Cortex and Notoginseng Radix and a composition for prevention and treatment of periodontal disease containing the herbal mixture extract as an active ingredient, more precisely, a herbal mixture extract having activities of inhibiting the generation and activation of osteoclasts by enhancing the expression of osteoprotegerin (OPG) in osteoblasts, preventing alveolar bone from destruction by inhibiting the proliferation of osteoclasts and maintaining the growth of periodontal ligament cells and gingival fibroblasts, and a composition for prevention and treatment of periodontal disease containing the above mixture as an active ingredient.

The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and / or a pharmaceutical composition, in particular to the use of such a preparation / composition for preventing or treating disorders associated with bone metabolism and immune function.